Clinical Trials Browser

Interventional × Lung Neoplasms × Ramucirumab × Clear all

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-01-23

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2 Completed

166 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Withdrawn

Lung Neoplasms

NCT01168973 2019-09-25

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Phase 3 Completed

1,253 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01160744 2019-09-13

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

280 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms